Roivant Sciences Ltd. (NASDAQ:ROIV) is Tyro Capital Management LLC's 6th Largest Position

Tyro Capital Management LLC raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 20.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,108,283 shares of the company's stock after acquiring an additional 353,307 shares during the quarter. Roivant Sciences makes up approximately 8.2% of Tyro Capital Management LLC's investment portfolio, making the stock its 6th largest position. Tyro Capital Management LLC owned 0.29% of Roivant Sciences worth $24,941,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its stake in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Roivant Sciences during the fourth quarter valued at about $39,000. PNC Financial Services Group Inc. grew its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after buying an additional 3,426 shares during the period. Finally, Blue Trust Inc. raised its holdings in Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after buying an additional 6,667 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 1.8%

NASDAQ ROIV traded up $0.20 during trading hours on Tuesday, hitting $11.04. 4,631,337 shares of the company's stock were exchanged, compared to its average volume of 5,588,607. The firm has a market cap of $7.88 billion, a price-to-earnings ratio of -73.60 and a beta of 1.23. The stock has a 50-day simple moving average of $10.52 and a 200 day simple moving average of $11.07. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of Roivant Sciences stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. The trade was a 27.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares in the company, valued at $456,501,538.17. This trade represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,223,959 shares of company stock worth $13,420,035 in the last quarter. 7.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on ROIV. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.